Cosmo Pharmaceuticals finished the third phase of clascoterone solution clinical trials. The medicine is intended for topical application and blocks the hormone that causes hair loss. One thousand four hundred sixty-five men from the US and Europe took part in the studies, the creators reported.
During the first stage, hair growth in participants rose by 5.39 times compared to placebo—a gain of 539%. In the second stage, efficacy reached 168%. Scientists attributed the difference to data variability typical for such research.
Specialists noted that the novel cream acts locally and barely affects the body overall, which lessens the hazard of adverse reactions. Previously, patients had to choose between minimally effective treatments and medicines with systemic impact. In the upcoming months, the firm intends to conclude trials and submit paperwork for drug certification and the start of large-scale manufacturing.
About the Author
